Friday, April 3, 2026
22 C
Bengaluru

Key Challenges Facing Indian Pharma

Suresh Subramanian, talks about the challenges and way forward for Indian Pharma companies.

Highlights of the discussion:

With the Second Wave hitting India, customers (patients and physicians) will continue to socially distance themselves in the foreseeable future. Pharma must use the field force for reach and relationship and digital for frequency and personalised content for better customer experience.

The pandemic has made doctors adopt Telehealth in a substantial way to shore up their revenues and this will continue to be one of their channels to engage patients. Telehealth along with EMR/EHR, digital therapeutics and wearables is enabling doctors to better care for their patients. There are many ways in which pharma can support the digital evolution of doctors.

Most pharma companies have multiple divisions and the data from these divisions remain in silos and need to be integrated to better understand customers, their needs and build personas that enable wider segmentation for personalisation of communications.

Data will become the New Supervisor and field sales managers will have to transform into Customer Experience Managers and Medical Reps will have to evolve into Media Planners to be able to connect with doctors based on their channel preferences.

As more and more people search the Internet in their efforts to self-manage, Wellness sector will gain momentum and this is where pharma can work with other partners to provide health related information and products via digital channels to people who are online 24×7.

Some questions that Suresh Subramanian will answer in today’s session:

Register now to receive your email invitation – https://www.credoweb.in/discussion/630/key-challenges-facing-pharma-industry-and-the-way-forward

You can listen to 50+ webinars and Q&A sessions by over 20 thought leaders from India and broad on a wide range of topics that impact pharma business.

Hot this week

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled

From Gas Cylinders to ICU Beds: How the Gulf...

Topics

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...

Excellence or Mediocrity—What Are You Building?

Excellence is a choice. So is Mediocrity Excellence is a...

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed...
spot_img

Related Articles

spot_imgspot_img